HDV is a viral infection that causes liver inflammation, sometimes leading to serious liver damage. It is caused by the hepatitis D virus (HDV) and is considered to be the most severe form of viral hepatitis in humans due to more rapid progression toward liver-related death and hepatocellular carcinoma. HDV requires hepatitis B virus (HBV) for its replication. HDV infection occurs as co-infection or as super-infection with HBV. The market size of Hepatitis D Virus (HDV) in the 7MM was found to USD 285.1 million in 2017, which is expected to increase during the forecast period.
According to the World Health Organization (WHO) estimates, Hepatitis D virus (HDV) affects globally nearly 5% of people who have a chronic infection with hepatitis B virus (HBV). According to the research study of Chen et al. (2019), the global prevalence of HDV is 0.98%, and approximately 10.58% of the global HBsAg carriers are also coinfected with HDV, which means the global burden of HDV infection is approximately 62–72 million individuals.
DelveInsight's "Hepatitis D Market Insights, Epidemiology, and Market Forecast 2030" reports deliver an in-depth understanding of the Hepatitis D Market, historical and forecasted epidemiology, the pipeline insight as well as the Hepatitis D market size and shares analysis in the seven major markets (7MM) (i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.
Hepatitis D Market Trends Analysis
The Hepatitis D market analysis section of the report helps to build a detailed comprehension of the historical, current, and forecasted Hepatitis D market trends and growth by analysing the impact of current therapies on the market, unmet needs, drivers, and barriers and demand for better technology.
The report gives complete detail of Hepatitis D market size and shares of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, and view of the key opinion leaders.
Hepatitis D Epidemiology Forecast
The Hepatitis D epidemiology section covers insights about historical and current Hepatitis D patient pool and forecasted trends for every seven major countries (i.e., the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Hepatitis D Pipeline Analysis
The Hepatitis D Pipeline and Drugs Uptake section focus on the rate of uptake of the potential drugs recently launched in the Hepatitis D market or expected to get launched in the market during the study period. The analysis covers the Hepatitis D market uptake by drugs, patient uptake by therapies, and drug sales.
Hepatitis D Virus (HDV) Companies operating in the market include MYR Pharmaceuticals, Hepatera, Eiger Biopharmaceuticals, Janssen Pharmaceuticals, and many others. Hepatitis D Virus (HDV) therapies covered in the report include Hepcludex/Bulevirtide, Lonafarnib, Peginterferon Lambda, JNJ-73763989 (JNJ-3989), and many more.
For more details, visit: Hepatitis D Market Trends